Skip to content

Total debt at other companies

Bruker logo
BrukerBRKR
$1.67B-20.9%
Revvity logo
RevvityRVTY
$3.94B+17.8%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$987.3M-28.4%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Danaher logo
DanaherDHR
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$311.4M-1.5%
Gross profit$208.3M-2.9%
Operating income$75.5M+95.0%
Net income$51.0M+126%
EPS (diluted)$0.32+129%

Balance sheet

See full
Cash & equivalents$209.8M+49.2%
Total equity$2.1B+3.3%
Total assets$2.6B-3.5%

Cash flow

See full
Operating cash flow$86.7M+111%
CapEx$9.1M-10.2%
Free cash flow$77.6M+150%

Valuation

See full
Market cap$9.07B-11.8%
Enterprise value$9.15B-13.6%
P/E60.6×+13.6×
P/S7.5×-1.0×

Profitability

See full
Gross margin65%-0.8pp
Operating margin14.2%-7.9pp
Net margin10.9%-6.7pp
FCF margin22.3%+4.0pp

Returns & leverage

See full
Return on equity6.5%-3.9pp
Debt / equity0.1×-0.1×
Current ratio4.5×+0.8×

Where this comes from

Calculated from Bio-Techne’s reported figures.

Plus components not separately reported this period.

The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Techne's total debt?
Bio-Techne (TECH) reported total debt of $290.32M in Q1 2026.
How has Bio-Techne's total debt changed year-over-year?
Bio-Techne's total debt decreased by 31.4% year-over-year, from $423.5M to $290.32M.
What is the long-term trend for Bio-Techne's total debt?
Over 4 years (2021 to 2025), Bio-Techne's total debt has grown at a 1.4% compound annual growth rate (CAGR), from $420.55M to $444.06M.
What does total debt mean?
The total amount of money the company owes to creditors and lenders.
How do you interpret total debt?
An increase suggests higher financial leverage and potential interest expense pressure, while a decrease indicates deleveraging and improved balance sheet strength.
How does total debt compare across companies?
Peers in the life sciences and diagnostics sector typically maintain moderate debt levels to fund R&D and strategic acquisitions, with ratios often benchmarked against EBITDA to assess solvency.